Literature DB >> 9177755

Isotope ratio mass spectrometry, compared with conventional mass spectrometry in kinetic studies at low and high enrichment levels: application to lipoprotein kinetics.

F Pont1, L Duvillard, C Maugeais, A Athias, L Perségol, P Gambert, B Vergès.   

Abstract

The aim of the present study was to compare the performances of gas chromatography/mass spectrometry (GC/MS) and gas chromatography/combustion/isotope ratio mass spectrometry (GC/C/IRMS) in stable isotope kinetic studies. In the analysis of cholesterol and leucine, GC/C/IRMS gave precise and linear results over a large scale of 13C enrichment (-22 to +760 delta/1000 for cholesterol, -26 to +600 delta/1000 for leucine). Compared with GC/MS, GC/C/IRMS was much more accurate and reproducible, especially at low [13C]-cholesterol enrichment (-12 delta/1000), with cholesterol samples ranging from 0.11 to 17 ng. Cholesterol ester kinetics in rabbit plasma low-density lipoproteins was studied after injection of 3 mg [3,4-(13)C]cholesterol. A smooth and regular kinetic curve was obtained with GC/C/IRMS; results were much less reproducible with GC/MS. Finally, the performances of GC/C/IRMS were demonstrated in the simultaneous kinetic study of three human plasma apolipoproteins during a primed constant infusion of 0.7 mg.kg-1.h-1 L-[l-13C]leucine. Kinetic curves were obtained in very-low-density lipoproteins and low-density lipoproteins for apolipoprotein B100, and in high-density lipoproteins for apolipoproteins AI and AIL.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9177755     DOI: 10.1006/abio.1997.2130

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  5 in total

1.  Application of high-precision isotope ratio monitoring mass spectrometry to identify the biosynthetic origins of proteins.

Authors:  I Apostol; P D Brooks; A J Mathews
Journal:  Protein Sci       Date:  2001-07       Impact factor: 6.725

2.  Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment.

Authors:  Christophe Marçais; Bruno Verges; Sybil Charrière; Valérie Pruneta; Micheline Merlin; Stéphane Billon; Laurence Perrot; Jocelyne Drai; Agnès Sassolas; Len A Pennacchio; Jamila Fruchart-Najib; Jean-Charles Fruchart; Vincent Durlach; Philippe Moulin
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

3.  Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes.

Authors:  B Vergès; E Florentin; S Baillot-Rudoni; S Monier; J M Petit; D Rageot; P Gambert; L Duvillard
Journal:  Diabetologia       Date:  2008-06-05       Impact factor: 10.122

4.  Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes.

Authors:  Bruno Vergès; Emmanuel Florentin; Sabine Baillot-Rudoni; Jean-Michel Petit; Marie Claude Brindisi; Jean-Paul Pais de Barros; Laurent Lagrost; Philippe Gambert; Laurence Duvillard
Journal:  J Lipid Res       Date:  2009-01-22       Impact factor: 5.922

5.  Measurement of reverse cholesterol transport pathways in humans: in vivo rates of free cholesterol efflux, esterification, and excretion.

Authors:  Scott Turner; Jason Voogt; Michael Davidson; Alex Glass; Salena Killion; Julie Decaris; Hussein Mohammed; Kaori Minehira; Drina Boban; Elizabeth Murphy; Jayraz Luchoomun; Mohamad Awada; Richard Neese; Marc Hellerstein
Journal:  J Am Heart Assoc       Date:  2012-08-24       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.